Who this is for

Asset × indication diligence for people in biotech — funds, biotech and pharma teams, and sophisticated self-directed researchers. Not mass-market retail investing.

What it is

A structured, evidence-linked memo built from a persisted public regulatory and trials graph (FDA label-quality links, outcomes, analogs) with optional live supplements (ClinicalTrials.gov, PubMed) clearly labeled T3.

What it is not

• Not investment advice, buy/sell, or partner recommendations
• No numeric probability of success or valuation
• Not a substitute for primary sources, dataroom review, or licensed commercial data
• Private or proprietary documents are not ingested in the public pilot (M3+)

Coverage honesty

Reports disclose graph coverage (trials, targets, label-quality links). Thin coverage triggers live supplements; gaps remain explicit in the evidence-quality domain.

Evidence tiers

• T1 — persisted public graph
• T3 live — fetched at run time, not yet ingested
• T3 project — user-provided assumptions/documents (when enabled)